|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
adolescents
adults
children aged 6 years and older
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:R03DX09
|
|
gptkbp:brand
|
gptkb:Nucala
|
|
gptkbp:contraindication
|
hypersensitivity to mepolizumab
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:mepolizumab
|
|
gptkbp:halfLife
|
16-22 days
|
|
gptkbp:hasMolecularFormula
|
C6452H9952N1728O2016S44
|
|
gptkbp:indication
|
gptkb:hypereosinophilic_syndrome
gptkb:eosinophilic_granulomatosis_with_polyangiitis
severe eosinophilic asthma
chronic rhinosinusitis with nasal polyps
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:mechanismOfAction
|
gptkb:IL-5_antagonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
fatigue
headache
back pain
injection site reaction
upper respiratory tract infection
|
|
gptkbp:target
|
gptkb:interleukin-5
|
|
gptkbp:bfsParent
|
gptkb:mepolizumab
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nucala
|